Edition:
United Kingdom

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

2,351JPY
17 Nov 2017
Change (% chg)

¥-32 (-1.34%)
Prev Close
¥2,383
Open
¥2,353
Day's High
¥2,365
Day's Low
¥2,338
Volume
1,724,100
Avg. Vol
1,109,152
52-wk High
¥2,748
52-wk Low
¥2,073

Select another date:

Wed, Oct 18 2017

BRIEF-Mitsubishi Tanabe Pharma completes purchase of NeuroDerm

Oct 18Mitsubishi Tanabe Pharma Corp * Says it completed purchase of NeuroDerm Ltd * Purchase plan was announced on July 24 Source text in Japanese:https://goo.gl/LcG5Lm Further company coverage: (Beijing Headline News)

BRIEF- Mitsubishi Tanabe Pharma sells drug sales unit

* Says it sold 100 percent stake in a drug sales unit to Nipro, on Oct. 1

BRIEF-Neuroderm calls shareholders meeting to approve Mitsubishi Tanabe acquisition

* Neuroderm announces extraordinary general meeting of shareholders to approve acquisition by Mitsubishi Tanabe Pharma Corporation Source text for Eikon: Further company coverage:

Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 billion

TOKYO/TEL AVIV Japan's Mitsubishi Tanabe Pharma Corp has agreed to buy Israeli drug maker Neuroderm for $1.1 billion in cash as part of a strategy to grow its business in the United States.

UPDATE 3-Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln

* Neuroderm shares up 15 pct in premarket trade (Adds Neuroderm shares up 15 pct in premarket trade)

Japan's Mitsubishi Tanabe Pharma to buy Israel's Neuroderm for $1.1 bln

TOKYO, July 24 Japan's Mitsubishi Tanabe Pharma Corp said on Monday it will acquire Israeli drug maker Neuroderm for $1.1 billion in an all-cash deal to expand its overseas business.

BRIEF- Mitsubishi Chemical Holdings consolidated subsidiary to buy NeuroDerm for about $1.1 bln

* Says its consolidated subsidiary Mitsubishi Tanabe Pharma Corp will buy NeuroDerm Ltd, for about $1.1 billion (about 124.1 billion yen), $39 per share, effective October

BRIEF-Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma for $1.1 bln

* Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma corporation for US$1.1 billion in cash

BRIEF-R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

Select another date: